Evaluation of urinary corticosterone as a biomarker of stress in rats using fenitrothion as a chemical stressor.
Regulatory guidelines for pharmaceutical toxicity studies recommend using one dose near the maximum tolerated. At that level significant toxicities may occur, leading to systemic stress and secondary immune suppression which can be difficult to differentiate from a primary drug effect. Therefore, there is a need for a biomarker of stress applicable to toxicity studies. This study evaluated urinary corticosterone as a biomarker, using as a pharmacologic stressor fenitrothion, which was previously shown not to cause primary immune suppression. Rats were administered fenitrothion orally at 20 and 30 mg/kg daily for 2 or 8 days, with matched vehicle controls (n = 6/group). Urine was collected for 6 and 24 h, before treatment and on Day 2 and Day 8. Urine was assayed for corticosterone, separately for the first 6 h of collection and for the whole 24 h sample. Animals were euthanized on Day 3 or Day 9 and lymphoid tissue samples were collected, weighed and examined histologically. Treated rats showed neurologic signs following treatment. Findings also included time- and dose-dependent decreases in body weight and spleen and thymus weight decreases supra-proportional to body weight on Day 9. Histologic changes were mild at a dose of 20 mg/kg, but significant at 30 mg/kg, consisting of lymphocytolysis at Day 3 and lymphoid depletion at Day 9. Urine corticosterone levels were increased on Day 2 and Day 8, in the 6-h samples, but not the 24-h ones, at both dose levels. Based on the results, urine corticosterone appears to be a sensitive biomarker of systemic stress caused by fenitrothion. Other chemical stressors should be evaluated in a similar manner in order to fully validate urine corticosterone measurement as a stress biomarker.
a Drug Safety Research and Development, Pfizer Global Research and Development , Groton , CT , USA.
Jean-Martin
JM
Lapointe
a Drug Safety Research and Development, Pfizer Global Research and Development , Groton , CT , USA.
Patricia A
PA
Snyder
a Drug Safety Research and Development, Pfizer Global Research and Development , Groton , CT , USA.
William J
WJ
Reagan
D016907:Adverse Drug Reaction Reporting Systems; D000818:Animals; D015415:Biomarkers / Q000652:urine*; D001835:Body Weight; D003345:Corticosterone / Q000652:urine*; D064420:Drug-Related Side Effects and Adverse Reactions / Q000175:diagnosis* / Q000378:metabolism; D005278:Fenitrothion / Q000008:administration & dosage / Q000009:adverse effects*; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects*; D008297:Male; D051381:Rats; D017207:Rats, Sprague-Dawley; D013154:Spleen / Q000187:drug effects / Q000473:pathology; D013312:Stress, Physiological / Q000502:physiology*; D013950:Thymus Gland / Q000187:drug effects / Q000473:pathology
D015415:Biomarkers; D007166:Immunosuppressive Agents; D005278:Fenitrothion; D003345:Corticosterone
Stress; biomarker; corticosterone; fenitrothion; rat